Financial Performance - The company reported a basic earnings per share of -0.7100 yuan for 2024, a decrease of 407.14% compared to -0.1400 yuan in 2023 [1] - The net profit for 2024 was -0.61 billion yuan, representing a decline of 408.33% from -0.12 billion yuan in 2023 [1] - Operating revenue decreased by 28.31% to 1.19 billion yuan in 2024 from 1.66 billion yuan in 2023 [1] - The return on equity was -23.56% in 2024, a significant drop from -3.95% in 2023 [1] - The net asset per share decreased by 21.07% to 2.66 yuan in 2024 from 3.37 yuan in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 19.7735 million shares, accounting for 32.91% of the circulating shares, with a decrease of 2.7696 million shares compared to the previous period [2] - Shanghai Tiancong Enterprise Management Center (Limited Partnership) holds 600.00 thousand shares, representing 9.98% of the total share capital, with no change [2] - Tian Lifeng holds 490.52 thousand shares, accounting for 8.16% of the total share capital, with no change [2] - New entrants to the top ten shareholders include Cha Qin and Wang Guolin, holding 180.00 thousand shares (3.00%) and 60.28 thousand shares (1.00%) respectively [2] - Shareholders Luo Wen and Yu Haihong have exited the top ten shareholders list [2] Dividend Policy - The company has announced no distribution or capital increase for the current period [3]
辰光医疗:2024年报净利润-0.61亿 同比下降408.33%